Medical affairs teams handle a contract family that looks deceptively simple. An external investigator proposes a study, the company agrees to support it, and the resulting agreement runs to a fraction of the length of a sponsored clinical trial agreement. The brevity is real. The reduction in obligations is not.
In an investigator initiated study, sometimes called an investigator sponsored study, the investigator or their institution takes on the regulatory role of sponsor. They hold the protocol, they carry the submission responsibilities, and they answer for the conduct of the research. The supporting company provides funding, study product, data or some combination, and steps back from the operational control it would exercise in its own trial.
That shift changes what the agreement needs to say. The company can no longer direct the study, so it cannot rely on the protocol control levers that sit in a standard clinical trial agreement. What it can do is define the support precisely, fix the publication and safety expectations in writing, and track the commitments it has made across a portfolio of studies that typically runs for years.
What changes when the investigator is the sponsor
The differences between a company-sponsored trial and an investigator initiated study are not cosmetic. They reallocate responsibility in ways that matter for both compliance and contracting.
- Protocol authorship moves, the investigator designs the study, so the agreement records support for a protocol rather than granting the company rights to amend it at will.
- Regulatory filings shift, submissions and the associated reporting duties belong to the sponsor-investigator, which is precisely why the company's own pharmacovigilance obligations must be stated explicitly.
- Monitoring rights narrow, the company usually has no source data verification right, so assurance comes from milestone reporting and a defined final study report instead.
- Publication control inverts, the investigator expects to publish, and the company's interest is normally limited to advance review and protection of confidential information.
- Support becomes the deliverable, the company's performance is measured by whether funding tranches, product shipments and data transfers arrive as promised, which is a supply chain question as much as a legal one.
Because the company's role is supportive rather than directive, the agreement works best when it is precise about inputs and light on control. Every obligation the company accepts should be one it can actually perform and evidence, since an unmet support commitment is visible to an investigator community that talks to each other.
Support for investigator initiated research is scrutinized for the same reason speaker fees and consulting arrangements are. Funding decisions should follow a documented scientific review, payment should be tied to milestones at defensible values, and the review committee record should be retained alongside the agreement so the rationale survives staff turnover.
The obligations that stay with the supporting company
Shifting sponsorship does not empty the company's side of the agreement. Five obligation families recur across almost every investigator initiated study and each one needs an owner and a due date.
- Safety information handling. Adverse event information reaching the company must be processed under its own pharmacovigilance obligations, with the reporting route and timelines written into the agreement rather than assumed.
- Product supply and accountability. Where study drug or device is supplied, quantities, shipment schedule, labeling, storage conditions and the return or destruction of unused product all become tracked commitments.
- Milestone payments. Funding is normally released against enrollment, interim reporting or database lock, and each tranche is a dated obligation with a condition attached that someone must verify.
- Publication and review windows. The company typically receives a defined period to review a draft manuscript for confidential information, and that window is short enough to be missed without a calendar entry.
- Transparency and disclosure. Payments and product transfers of value may require reporting under applicable transparency regimes, which depends on capturing the transfer accurately at the time it happens.
A five-step roadmap for managing an investigator study portfolio
Step 1, standardize the review gate
Every proposal should pass a documented scientific and compliance review before any commitment is discussed. Recording the committee decision, the scientific rationale and the value assessment in one place is what makes the support defensible later if it is ever questioned.
Step 2, template the agreement by support type
Funding only, product only, data access and combinations each need a different set of clauses. Maintaining separate templates prevents the common failure of a funding agreement that never mentions drug accountability because product was added after signature.
Step 3, extract obligations at execution
At signature, pull the payment milestones, supply schedule, reporting dates, publication window and study end date into structured fields with named owners. This is the single change that most reliably prevents support commitments from being quietly missed.
Step 4, monitor the study calendar
Investigator studies run long and staff change. A recurring review of active studies against their milestones catches stalled research, expired supply commitments and studies that have effectively ended without a final report.
Step 5, close the study formally
Define what closure requires, final report received, unused product reconciled, final payment released, publication reviewed, and hold the study open until each is evidenced. Portfolios accumulate zombie studies precisely because closure is never defined.
Track study support commitments to their close
Aavenir extracts milestones, supply schedules and reporting dates from executed study agreements and assigns each to a named owner.
Why portfolio visibility matters more than document quality
Most medical affairs teams draft these agreements well. What they lack is a portfolio view. A company supporting several dozen investigator initiated studies concurrently will have funding tranches, shipment obligations, review windows and final report deadlines distributed across as many documents, held by owners who rotate through the role every couple of years. The practical failures are almost never drafting failures. They are a payment milestone nobody released, a supply commitment that outlived the manufacturing campaign, a publication review window that lapsed, or a study that has not reported in three years and that nobody has formally closed. A structured obligation register fixes this in a way a better template cannot, because the problem is not what the agreement says but whether anyone is reading it after signature. The same argument applies across life sciences obligation management generally.
Support types and the obligations they create
The support model determines the obligation profile. Mapping them at the review stage rather than after signature keeps the agreement and the operational reality aligned.
| Support type | Primary company duty | Key tracked date | Common failure |
|---|---|---|---|
| Funding only | Release milestone payments | Milestone verification date | Tranche released without evidence |
| Study product supply | Ship, label and reconcile product | Shipment and expiry dates | Unused product never reconciled |
| Product plus funding | Both, on separate schedules | Whichever falls first | Schedules tracked in different systems |
| Data or sample access | Transfer under agreed scope | Transfer and destruction dates | Scope creep beyond the agreement |
| In-kind services | Provide named services only | Service completion date | Perceived direction of the study |
Investigator initiated research is valuable precisely because it is independent, and the contracting should protect that independence rather than erode it. The discipline worth building is not a longer agreement but a shorter distance between what the company promised and what the company can see. Review every proposal through a documented gate, template by support type, extract the commitments at signature, and define what closure means before the study starts. Teams that do this run larger portfolios with fewer surprises, and they can answer the two questions that matter to compliance and finance, what have we committed to and what remains outstanding. For the sponsored side of the same portfolio, see clinical trial agreement automation.
For related guidance, see Clinical trial site payment terms: a tracking datasheet, Material transfer agreement management for biotech teams and The sponsor’s guide to CRO master service agreements.
